🚀 VC round data is live in beta, check it out!
IDEXX Laboratories Valuation Multiples
Discover revenue and EBITDA valuation multiples for IDEXX Laboratories and similar public comparables like Edwards Lifesciences, Siemens Healthineers, Wuxi AppTec, Alcon and more.
IDEXX Laboratories Overview
About IDEXX Laboratories
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.
Founded
1983
HQ
Employees
11.0K
Website
Sectors
Financials (LTM)
EV
$51B
IDEXX Laboratories Financials
IDEXX Laboratories reported last 12-month revenue of $4B and EBITDA of $2B.
In the same LTM period, IDEXX Laboratories generated $3B in gross profit, $2B in EBITDA, and $1B in net income.
Revenue (LTM)
IDEXX Laboratories P&L
In the most recent fiscal year, IDEXX Laboratories reported revenue of $4B and EBITDA of $2B.
IDEXX Laboratories expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $4B | XXX | $4B | XXX | XXX | XXX |
| Gross Profit | $3B | XXX | $3B | XXX | XXX | XXX |
| Gross Margin | 62% | XXX | 62% | XXX | XXX | XXX |
| EBITDA | $2B | XXX | $2B | XXX | XXX | XXX |
| EBITDA Margin | 35% | XXX | 35% | XXX | XXX | XXX |
| EBIT Margin | 32% | XXX | 32% | XXX | XXX | XXX |
| Net Profit | $1B | XXX | $1B | XXX | XXX | XXX |
| Net Margin | 25% | XXX | 25% | XXX | XXX | XXX |
| Net Debt | — | — | $668M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
IDEXX Laboratories Stock Performance
IDEXX Laboratories has current market cap of $51B, and enterprise value of $51B.
Market Cap Evolution
IDEXX Laboratories' stock price is $636.70.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $51B | $51B | 0.0% | XXX | XXX | XXX | $13.31 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialIDEXX Laboratories Valuation Multiples
IDEXX Laboratories trades at 11.8x EV/Revenue multiple, and 33.6x EV/EBITDA.
EV / Revenue (LTM)
IDEXX Laboratories Financial Valuation Multiples
As of March 11, 2026, IDEXX Laboratories has market cap of $51B and EV of $51B.
Equity research analysts estimate IDEXX Laboratories' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
IDEXX Laboratories has a P/E ratio of 47.0x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $51B | XXX | $51B | XXX | XXX | XXX |
| EV (current) | $51B | XXX | $51B | XXX | XXX | XXX |
| EV/Revenue | 11.8x | XXX | 12.0x | XXX | XXX | XXX |
| EV/EBITDA | 33.6x | XXX | 34.1x | XXX | XXX | XXX |
| EV/EBIT | 37.1x | XXX | 37.9x | XXX | XXX | XXX |
| EV/Gross Profit | 19.0x | XXX | 19.4x | XXX | XXX | XXX |
| P/E | 47.0x | XXX | 47.9x | XXX | XXX | XXX |
| EV/FCF | 47.9x | XXX | 48.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified IDEXX Laboratories Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
IDEXX Laboratories Margins & Growth Rates
IDEXX Laboratories' revenue in the last 12 month grew by 9%.
IDEXX Laboratories' revenue per employee in the last FY averaged $0.4M.
IDEXX Laboratories' rule of 40 is 44% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
IDEXX Laboratories' rule of X is 57% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
IDEXX Laboratories Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 9% | XXX | 9% | XXX | XXX | XXX |
| EBITDA Margin | 35% | XXX | 35% | XXX | XXX | XXX |
| EBITDA Growth | 11% | XXX | 11% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 44% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 57% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 15% | XXX | 15% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 9% | XXX | 9% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 6% | XXX | 6% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 30% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
IDEXX Laboratories Public Comps
See public comps and valuation multiples for other Medical Devices and Laboratory Services comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Edwards Lifesciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Siemens Healthineers | XXX | XXX | XXX | XXX | XXX | XXX |
| Wuxi AppTec | XXX | XXX | XXX | XXX | XXX | XXX |
| Alcon | XXX | XXX | XXX | XXX | XXX | XXX |
| ResMed | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
IDEXX Laboratories M&A Activity
IDEXX Laboratories acquired XXX companies to date.
Last acquisition by IDEXX Laboratories was on XXXXXXXX, XXXXX. IDEXX Laboratories acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by IDEXX Laboratories
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialIDEXX Laboratories Investment Activity
IDEXX Laboratories invested in XXX companies to date.
IDEXX Laboratories made its latest investment on XXXXXXXX, XXXXX. IDEXX Laboratories invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by IDEXX Laboratories
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout IDEXX Laboratories
| When was IDEXX Laboratories founded? | IDEXX Laboratories was founded in 1983. |
| Where is IDEXX Laboratories headquartered? | IDEXX Laboratories is headquartered in United States. |
| How many employees does IDEXX Laboratories have? | As of today, IDEXX Laboratories has over 11K employees. |
| Who is the CEO of IDEXX Laboratories? | IDEXX Laboratories' CEO is Jonathan J. Mazelsky. |
| Is IDEXX Laboratories publicly listed? | Yes, IDEXX Laboratories is a public company listed on Nasdaq. |
| What is the stock symbol of IDEXX Laboratories? | IDEXX Laboratories trades under IDXX ticker. |
| When did IDEXX Laboratories go public? | IDEXX Laboratories went public in 1991. |
| Who are competitors of IDEXX Laboratories? | IDEXX Laboratories main competitors are Edwards Lifesciences, Siemens Healthineers, Wuxi AppTec, Alcon. |
| What is the current market cap of IDEXX Laboratories? | IDEXX Laboratories' current market cap is $51B. |
| What is the current revenue of IDEXX Laboratories? | IDEXX Laboratories' last 12 months revenue is $4B. |
| What is the current revenue growth of IDEXX Laboratories? | IDEXX Laboratories revenue growth (NTM/LTM) is 9%. |
| What is the current EV/Revenue multiple of IDEXX Laboratories? | Current revenue multiple of IDEXX Laboratories is 11.8x. |
| Is IDEXX Laboratories profitable? | Yes, IDEXX Laboratories is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of IDEXX Laboratories? | IDEXX Laboratories' last 12 months EBITDA is $2B. |
| What is IDEXX Laboratories' EBITDA margin? | IDEXX Laboratories' last 12 months EBITDA margin is 35%. |
| What is the current EV/EBITDA multiple of IDEXX Laboratories? | Current EBITDA multiple of IDEXX Laboratories is 33.6x. |
| What is the current FCF of IDEXX Laboratories? | IDEXX Laboratories' last 12 months FCF is $1B. |
| What is IDEXX Laboratories' FCF margin? | IDEXX Laboratories' last 12 months FCF margin is 25%. |
| What is the current EV/FCF multiple of IDEXX Laboratories? | Current FCF multiple of IDEXX Laboratories is 47.9x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.